IGI Therapeutics and AbbVie (ABBV) announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases. Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. Subject to regulatory clearance, IGI will receive an upfront payment of $700M and is eligible to receive up to $1.225B in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie: A Strong Buy with Promising Growth Prospects and Stable Outlook
- AbbVie Buy Rating Supported by Strong Performance, Growth Prospects, and Strategic Positioning
- Epcoritamab Trial Update: A Potential Game-Changer in B-Cell Lymphoma Treatment
- AbbVie’s Promising Study on New NSCLC Treatment: A Potential Game-Changer
- Pfizer and AbbVie Advance Pediatric Infection Study with ATM-AVI